

Resource Summary Report

Generated by [NIF](#) on Sep 8, 2026

Daudi

RRID:CVCL_0008

Type: Cell Line

Proper Citation

RRID:CVCL_0008

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0008

Proper Citation: RRID:CVCL_0008

Description: Cell line Daudi is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: EBV-related Burkitt lymphoma

Defining Citation: [PMID:170370](#), [PMID:216485](#), [PMID:1325212](#), [PMID:2052620](#), [PMID:2140233](#), [PMID:2470097](#), [PMID:2985879](#), [PMID:2998993](#), [PMID:3026973](#), [PMID:3034807](#), [PMID:3080238](#), [PMID:3100061](#), [PMID:3116544](#), [PMID:3159941](#), [PMID:3518877](#), [PMID:3785169](#), [PMID:3874327](#), [PMID:3905596](#), [PMID:4122458](#), [PMID:4174339](#), [PMID:4178827](#), [PMID:4321974](#), [PMID:4364259](#), [PMID:4878906](#), [PMID:5021706](#), [PMID:6186604](#), [PMID:6200433](#), [PMID:6231253](#), [PMID:6286763](#), [PMID:6500159](#), [PMID:6547209](#), [PMID:6582512](#), [PMID:6592381](#), [PMID:6806672](#), [PMID:6935474](#), [PMID:6954533](#), [PMID:7316467](#), [PMID:7849311](#), [PMID:8176200](#), [PMID:8197130](#), [PMID:8301159](#), [PMID:8515068](#), [PMID:8558913](#), [PMID:8558920](#), [PMID:8568269](#), [PMID:8847894](#), [PMID:9192833](#), [PMID:9473234](#), [PMID:9510473](#), [PMID:9685479](#), [PMID:9737686](#), [PMID:9738977](#), [PMID:9973220](#), [PMID:10739008](#), [PMID:11021758](#), [PMID:11226526](#), [PMID:11894933](#), [PMID:12145705](#), [PMID:12967475](#), [PMID:14504097](#), [PMID:15028022](#), [PMID:16957166](#), [PMID:19358282](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20454443](#), [PMID:22460905](#), [PMID:22885699](#), [PMID:24590883](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29892436](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#)

Comments: Caution: TP53 mutation indicated incorrectly as being at c.637C>T in PubMed=2052620., Population: African; Kenyan., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Human variation panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of:

Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE), Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Daudi

Synonyms: DAUDI, NK-10A, NK-10a, NK 10a, NK10a, N, GM03190, GM3190, GM03190A, GM17346

Cross References: BTO:BTO_0001561, CLO:CLO_0002708, CLO:CLO_0013411, CLO:CLO_0013740, CLO:CLO_0050991, EFO:EFO_0002169, MCCL:MCC:0000141, CLDB:cl993, CLDB:cl994, CLDB:cl995, CLDB:cl996, CLDB:cl997, CLDB:cl998, CLDB:cl999, CLDB:cl5181, AddexBio:C0003010/4669, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CCL-213, ATCC:CRL-7917, BCRC:60192, BioGRID_ORCS_Cell_line:1081, BioSample:SAMN00808283, BioSample:SAMN01821546, BioSample:SAMN01821623, BioSample:SAMN03472413, BioSample:SAMN10987948, cancercellines:CVCL_0008, CCRID:1101HUM-PUMC000134, CCRID:1102HUM-NIFDC00053, CCRID:3101HUMTCHU140, CCRID:4201HUM-CCTCC00097, CCTCC:GDC0097, Cell_Model_Passport:SIDM00845, CGH-DB:9195-4, ChEMBL-Cells:ChEMBL3307579, ChEMBL-Targets:ChEMBL614281, CLS:302009, Coriell:GM03190, Coriell:GM17346, Cosmic:687838, Cosmic:906831, Cosmic:919135, Cosmic:929815, Cosmic:931102, Cosmic:932762, Cosmic:991548, Cosmic:996304, Cosmic:998716, Cosmic:1019315, Cosmic:1037701, Cosmic:1070708, Cosmic:1071878, Cosmic:1086326, Cosmic:1093789, Cosmic:1118470, Cosmic:1176616, Cosmic:1191690, Cosmic:1517663, Cosmic:1995384, Cosmic:2649240, Cosmic:2759407, Cosmic:2760061, Cosmic:2814537, Cosmic:2815216, Cosmic:2823073, Cosmic-CLP:906831, dbMHC:48767, DepMap:ACH-000786, DSMZ:ACC-78, DSMZCellDive:ACC-78, ECACC:85011437, ECACC:94071449, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10422-106C8, GDSC:906831, GEO:GSM99381, GEO:GSM862859, GEO:GSM862860, GEO:GSM862861, GEO:GSM862862, GEO:GSM886973, GEO:GSM888042, GEO:GSM960117, GEO:GSM960118, GEO:GSM960119, GEO:GSM960120, GEO:GSM1374459, GEO:GSM1669726, GEO:GSM3150242, GEO:GSM7701371, GEO:GSM7701372, IARC_TP53:143, IARC_TP53:21144, ICLC:HTL95024, IGRhCellID:Daudi, IHW:IHW09366, IPD-IMGT/HLA:10471, IZSLER:BS TCL 104, JCRB:JCRB9071, KCB:KCB 2012116YJ, KCLB:10213, LiGeA:CCLE_233, LINCS_LDP:LCL-2018, Lonza:490, NCBI_Iran:C112, PharmacDB:Daudi_283_2019, PRIDE:PXD004181, PRIDE:PXD012087, PRIDE:PXD030304, Progenetix:CVCL_0008, PubChem_Cell_line:CVCL_0008, RCB:RCB1640, TKG:TKG 0362, Wikidata:Q54828579

ID: CVCL_0008

Record Creation Time: 20220427T215744+0000

Record Last Update: 20260905T175125+0000

Ratings and Alerts

No rating or validation information has been found for Daudi.

Warning: Discontinued: ATCC; CRL-7917

Caution: TP53 mutation indicated incorrectly as being at c.637C>T in PubMed=2052620., Population: African; Kenyan., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Human variation panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 54 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Wang L, et al. (2026) A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies. *Journal of hematology & oncology*, 19(1).

Alsina M, et al. (2026) Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. *Cancer immunology research*, 14(4), 528.

Zhang Z, et al. (2026) A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. *Pharmaceuticals (Basel, Switzerland)*, 19(4).

Yao H, et al. (2026) Zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagy. *Blood science (Baltimore, Md.)*, 8(2), e00276.

Schneiderova P, et al. (2025) The SARS-CoV-2 trigger highlights host interleukin 1 genetics in Epstein-Barr virus reactivation. *Cell reports*, 44(7), 115859.

Domagala J, et al. (2025) Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. *Cancer research*, 85(13), 2448.

Zhang M, et al. (2025) Structures of butyrophilin multimers reveal a plier-like mechanism for V γ 9V δ 2 T cell receptor activation. *Immunity*, 58(7), 1660.

Ogawa A, et al. (2025) Adenosine kinase and ADAL coordinate detoxification of modified adenosines to safeguard metabolism. *Cell*.

Jeong Y, et al. (2025) Dual targeting of EZH2 and PD-L1 in Burkitt's lymphoma enhances immune activation and induces apoptotic pathway. *Frontiers in immunology*, 16, 1578665.

Beauchemin H, et al. (2025) Inhibiting the RNA helicase DDX3X in Burkitt lymphoma induces oxydative stress and impedes tumor progression in xenografts. *Frontiers in cell and developmental biology*, 13, 1642006.

Kok N, et al. (2025) CD28 signaling domain boosts persistence and in vivo anti-tumor activity of stem cell-derived CD19-CAR-NK cells. *iScience*, 28(6), 112548.

Billon E, et al. (2025) BTN2A1 acquisition through trogocytosis enhances V α 9V β 2 T cell cytotoxicity against autologous and cancer cells. *Cell reports*, 44(10), 116387.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. *Frontiers in immunology*, 16, 1518787.

Akhtar A, et al. (2025) Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity. *Cell reports. Medicine*, 6(3), 102021.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. *Cancer cell*, 42(5), 833.

Yu WW, et al. (2024) Skin immune-mesenchymal interplay within tertiary lymphoid structures promotes autoimmune pathogenesis in hidradenitis suppurativa. *Immunity*, 57(12), 2827.

McNutt SW, et al. (2024) Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation. *Research square*.

Takami M, et al. (2024) Anti-V α 24J β 18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an Fc γ RII (CD32)-dependent Manner. *Cancer research communications*, 4(2), 446.

Pfeffer K, et al. (2024) A method for screening functional anti-Treg antibodies using a Treg-like cell line. *Journal of leukocyte biology*.